Anastasios Tsolakidis

Ass. Professor

University of West Attica
Country flagGreece

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Objectives Patients with RA were at increased risk for COVID-19-associated hospitalization and death during the first year of the pandemic in Greece. We aimed to examine their outcomes after the SARS-Cov-2 Omicron, a more contagious but with milder clinical impacts variant, prevailed. Methods A retrospective, nationwide study was conducted between 1 January 2022 and 30 June 2022 in all RA patients under treatment and matched (1:5) on age, sex and region of domicile random general population comparators. Confirmed SARS-CoV-2 infections, hospitalizations and deaths, anti-rheumatic medications, prior COVID-19, vaccinations and anti-viral medications were recorded. Results Among 34 182 RA patients, infections (n = 5569, 16.29%), hospitalizations (n = 489, 1.43%) and deaths (n = 106, 0.31%) were more frequent than among comparators. Incidence rates per 1000 person/years of infection [IRR (95% CI):1.19 (1.16, 1.23)], hospitalization [IRR (95% CI):2.0 (1.82, 2.24)], and death [IRR (95% CI):1.81 (1.44, 2.27)] were increased in RA despite better vaccination coverage (89% vs 84%) and more frequent use of anti-viral medications (2.37% vs 1.08). Logistic regression analysis after correcting for age, sex, vaccinations, prior COVID-19, and anti-viral medications in SARS-CoV-2 infected RA patients and comparators revealed increased risk of hospitalization (OR: 2.02, 95% CI: 1.79, 2.27) and death [OR: 1.73, (95% CI: 1.36, 2.20)] in RA. Among infected RA patients, rituximab treatment conferred increased risks for hospitalization [OR: 6.12, (95% CI: 2.89, 12.92)] and death [OR: 12.06 (95% CI: 3.90, 37.31)], while JAK inhibitors increased only hospitalization risk [OR: 2.18 (95% CI: 1.56, 3.06)]. Conclusion RA remains a risk factor for hospitalization and death in an era of a relatively low COVID-19 fatality rate, pointing to the need of perseverance in vaccination programs and wider use of anti-viral medications.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Dimitris Kouis

Assistant Professor

University of West Attica

GREECE
View details

PANAGIOTA MITROU

Head

Ministry of Health

GREECE
View details

Elizabeth Lazaridou

Professor of Dermatology-Venereology

Aristotle University of Thessaloniki

GREECE
View details

Dimitrios Paraskevis

Professor

Ethniko kai Kapodistriako Panepistemio Athenon Iatrike Schole

GREECE
View details

Dimitra Ioanna Lampropoulou

Assistant Professor of Clinical Pharmacology

UNIVERSITY OF PELOPONNESE

GREECE
View details

Nikolaos Thomaidis

PROFESSOR

National and Kapodistrian University of Athens

GREECE
View details

Petros P Sfikakis

National and Kapodistrian University of Athens

GREECE
View details

Christos Skourlas

University of West Attica

GREECE
View details

Athina Markou

National and Kapodistrian University of Athens

GREECE
View details

George E Fragoulis

Rheumatologist

National and Kapodistrian University of Athens

GREECE
View details

Nikitas Karanikolas

Professor

University of West Attica

GREECE
View details